Update: AspenBio Pharma, Inc. to Host Conference Call to Discuss Preliminary Results of the AppyScore FDA Clinical Study on Jan. 21 at 9:00 AM ET

CASTLE ROCK, CO--(Marketwire - January 20, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, has changed the time for the conference call previously scheduled for Thursday, January 22, 2009 to now be held earlier, on Wednesday, January 21 at 9:00 a.m. Eastern time.

The company management will discuss initial preliminary data from its Food and Drug Administration clinical trial of AppyScore™, the world's first blood-based test as an aid in the diagnosis of human appendicitis. They will also discuss status of the FDA approval, product development and commercialization of AppyScore.

AspenBio's Vice-Chairman Greg Pusey will host the call, with presentations by president and CEO, Richard G. Donnelly, the company's new executive chairman, Daryl J. Faulkner and Dr. John Bealer, the co-inventor of AppyScore. This will be followed by a question and answer period.

Please call the conference telephone number 5-10 minutes prior to the start time:

Date: Wednesday, January 21, 2009
Time: 9:00 a.m. Eastern time (6:00 a.m. Pacific time)
Dial in number, U.S./Canada Toll-free: 1-800-896-8445
International (Toll): 1-785-830-1916
Conference ID: 7ASPENBIO

An operator will register your name and organization and ask you to wait until the call begins. If you have any difficulty connecting with the conference call, please contact the Liolios Group at (949) 574-3860.

A simultaneous webcast and replay of the call will be accessible via this link: http://viavid.net/dce.aspx?sid=00005C74.

An audio replay of the call will be available starting at noon Eastern time and through January 28, 2009:

U.S./Canada Toll-free: 1-800-723-5154
International (Toll): 1-402-220-2661
(No pass code required)

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its three first-generation blood-based human diagnostic tests designed as an aid in the diagnosis of human appendicitis. For more information, go to www.aspenbiopharma.com.